Floatz logo

LISPRO-PH20 COMPONENT RHUPH20

Smoldering Multiple Myeloma

Janssen Research & Development, LLCprotein_peptidePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Smoldering Multiple Myeloma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Regeneron Pharmaceuticals
Phase 3BB
FILGRASTIM
Regeneron Pharmaceuticals
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
cc-5013
Irene Ghobrial, MD
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB

View all 48 →

Same molecule, other indications

LISPRO-PH20 COMPONENT RHUPH20 is also rated in:

hereditary angioedemaDormant
B
Indicative ·
62 / 100
View asset →
melanomaDormant
B
Indicative ·
56 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →